Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047567 | 0.75 | CHRM3 (0.32) | — | |
| SCHEMBL4741973 | 0.74 | — | — | |
| SCHEMBL247419 | 0.71 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL28059928 | 0.71 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL120459 | 0.70 | SMN1; SMN2 (0.40) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL6129238 | 0.68 | SMN1; SMN2 (0.43) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL4582486 | 0.68 | SMN1; SMN2 (0.36) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL10446742 | 0.67 | APAF1 (0.39) | L3MBTL1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL4589801 | 0.67 | NPC1 (0.43) | L3MBTL1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9644150 | 0.63 | ALDH1A1 (0.32) | L3MBTL1ALDH1A1POLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12601929-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2026-04-14 | — | — | US | claimed |
| EP-4388349-B1 | CONTACT LENS | COOPERVISION INT LTD (GB) | 2025-03-12 | — | — | EP | claimed |
| US-12153288-B2 | Contact lens | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-11-26 | — | — | US | claimed |
| US-20240264469-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2024-08-08 | — | — | US | claimed |
| EP-4388349-A1 | CONTACT LENS | CooperVision International Limited (GB) | 2024-06-26 | — | — | EP | claimed |
| CN-118103737-A | Contact lens | 库博光学国际有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240041726-A1 | FOAMABLE COMPOSITION, USE THEREOF, AND PROCESS FOR ITS PREPARATION | CHATTEM, INC. | 2024-02-08 | — | — | US | claimed |
| WO-2023209329-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-02 | — | — | WO | claimed |
| US-20230350228-A1 | CONTACT LENS | COOPERVISION INTERNATIONAL LIMITED (GB) | 2023-11-02 | — | — | US | claimed |
| EP-4268814-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2023-11-01 | — | — | EP | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| US-9320705-B2 | Sensation modifying topical composition foam | FOAMIX PHARMACEUTICALS LTD. (IL) | 2016-04-26 | — | — | US | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| EP-2614860-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2013-07-17 | — | — | EP | claimed |
| US-20120237453-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | FOAMIX LTD. (IL) | 2012-09-20 | — | — | US | claimed |
| US-20080253973-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | FOAMIX LTD. (IL) | 2008-10-16 | — | — | US | claimed |
| US-20050000529-A1 | Method and compositions for imparting cooling effect to tobacco products | VECTOR TOBACCO INC. | 2005-01-06 | — | — | US | claimed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | claimed |
| US-6592884-B2 | Food, cosmetics, drugs; cooling skin, mouth | NESTEC S.A. (CH) | 2003-07-15 | — | — | US | claimed |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | NESTEC S.A. (CH) | 2002-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | PKN2, OPRD1, PKN1 | TYR 440/4885L3MBTL1 3770/4885ALDH1A1 484/4885 |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | ECH1, KMO, PKN1 | TYR 47/4885L3MBTL1 3305/4885ALDH1A1 840/4885 |
| US-12601929-B2 | Contact lens | TRPM8, TRPM7, TRPM5 | TYR 2161/4885L3MBTL1 3377/4885ALDH1A1 4075/4885 |
| US-20080253973-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | TRPA1, GPR35, TRPV1 | TYR 446/4885L3MBTL1 4878/4885ALDH1A1 2137/4885 |
| US-20120237453-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | TRPA1, GPR35, TRPV1 | TYR 446/4885L3MBTL1 4878/4885ALDH1A1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.